|
|
Volumn 10, Issue 5, 2015, Pages e23-e25
|
|
Response to crizotinib/erlotinib combination in a patient with a primary EGFR-mutant adenocarcinoma and a primary c-met-amplified adenocarcinoma of the lung
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMINO ACID;
CRIZOTINIB;
CYTOCHROME P450 3A4;
CYTOKERATIN 20;
CYTOKERATIN 5;
CYTOKERATIN 6;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
ESTROGEN RECEPTOR;
NAPSIN A;
PROGESTERONE RECEPTOR;
PROTEIN;
PROTEIN P63;
SCATTER FACTOR;
THYROID TRANSCRIPTION FACTOR 1;
TRANSCRIPTION FACTOR CDX2;
TRANSCRIPTION FACTOR GATA 3;
TRANSCRIPTION FACTOR PAX8;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC AGENT;
EGFR PROTEIN, HUMAN;
PYRAZOLE DERIVATIVE;
PYRIDINE DERIVATIVE;
SCATTER FACTOR RECEPTOR;
ADVERSE OUTCOME;
AGED;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BREAST CANCER;
BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA;
CANCER RECURRENCE;
CANCER STAGING;
CANCER THERAPY;
CASE REPORT;
CHROMOSOME 7;
COMPETITIVE INHIBITION;
COMPUTER ASSISTED TOMOGRAPHY;
DNA SEQUENCE;
EXON;
EXPERIMENTAL THERAPY;
FEMALE;
FLUORESCENCE IN SITU HYBRIDIZATION;
FOLLOW UP;
GENE AMPLIFICATION;
GENE MUTATION;
GENOTYPE;
HUMAN;
HUMAN TISSUE;
IMMUNOHISTOCHEMISTRY;
LEG EDEMA;
LUNG ADENOCARCINOMA;
LUNG BIOPSY;
LUNG NODULE;
LUNG TUMOR;
LYMPHADENOPATHY;
MEDICAL HISTORY;
MOLECULARLY TARGETED THERAPY;
OFF LABEL DRUG USE;
PHASE 1 CLINICAL TRIAL;
POLYMERASE CHAIN REACTION;
PRIORITY JOURNAL;
SECOND CANCER;
SMOKING;
SPINAL CORD LESION;
THYROID PAPILLARY CARCINOMA;
TREATMENT INDICATION;
TREATMENT RESPONSE;
WILD TYPE;
ADENOCARCINOMA;
GENETICS;
LUNG NEOPLASMS;
MUTATION;
NEOPLASMS, MULTIPLE PRIMARY;
ADENOCARCINOMA;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ERLOTINIB HYDROCHLORIDE;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MOLECULAR TARGETED THERAPY;
MUTATION;
NEOPLASMS, MULTIPLE PRIMARY;
PROTO-ONCOGENE PROTEINS C-MET;
PYRAZOLES;
PYRIDINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 84938245322
PISSN: 15560864
EISSN: 15561380
Source Type: Journal
DOI: 10.1097/JTO.0000000000000448 Document Type: Article |
|
Times cited : (18)
|
|
References (4)
|
